Stock Information

• This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
  Fri, Apr 3, 2026 2:17 PM
• Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors?
  Fri, Apr 3, 2026 11:12 AM
• Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP
  Thu, Apr 2, 2026 5:03 PM
• Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript
  Thu, Apr 2, 2026 4:32 PM
• Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint
  Thu, Apr 2, 2026 2:07 PM
• Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
  Thu, Apr 2, 2026 9:00 AM
• Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
  Thu, Apr 2, 2026 9:00 AM
• Roivant Launches Phase 2b/3 Brepocitinib Trial In Lichen Planopilaris As Batoclimab Fails Primary Endpoint In Phase 3 Thyroid Eye Disease Studies
  Thu, Apr 2, 2026 5:07 AM
• S&P 500 Futures Climb in Premarket Trading; United Therapeutics, Alcoa Lead
  Mon, Mar 30, 2026 7:31 AM
• Reported Saturday, Roivant's Priovant Therapeutics Wins FDA Priority Review For Brepocitinib After Phase 3 VALOR Trial Meets Primary And All Nine Key Secondary Endpoints In Dermatomyositis
  Mon, Mar 30, 2026 2:46 AM

Financial data not available